title: Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels.
abstract: OBJECTIVE
  Antibodies form an important class of cancer therapeutics, and there is intense interest in using them for imaging applications in diagnosis and monitoring of cancer treatment. Despite the expanding body of knowledge describing pharmacokinetic and pharmacodynamic interactions of antibodies in vivo, discrepancies remain over the effect of antigen expression level on tumoral uptake with some reports indicating a relationship between uptake and expression and others showing no correlation.
  
  
  METHODS
  Using a cell line with high epithelial cell adhesion molecule expression and moderate epidermal growth factor receptor expression, fluorescent antibodies with similar plasma clearance were imaged in vivo. A mathematical model and mouse xenograft experiments were used to describe the effect of antigen expression on uptake of these high-affinity antibodies.
  
  
  RESULTS
  As predicted by the theoretical model, under subsaturating conditions, uptake of the antibodies in such tumors is similar because localization of both probes is limited by delivery from the vasculature. In a separate experiment, when the tumor is saturated, the uptake becomes dependent on the number of available binding sites. In addition, targeting of small micrometastases is shown to be higher than larger vascularized tumors.
  
  
  CONCLUSIONS
  These results are consistent with the prediction that high affinity antibody uptake is dependent on antigen expression levels for saturating doses and delivery for subsaturating doses. It is imperative for any probe to understand whether quantitative uptake is a measure of biomarker expression or transport to the region of interest. The data provide support for a predictive theoretical model of antibody uptake, enabling it to be used as a starting point for the design of more efficacious therapies and timely quantitative imaging probes.
authors.affiliation: Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: Greg M
authors.initials: GM
authors.lastname: Thurber
authors.forename: Ralph
authors.initials: R
authors.lastname: Weissleder
mesh_terms: D000818:Animals; D000906:Antibodies / Q000378:metabolism*; D019138:Antibodies, Blocking / Q000378:metabolism; D000941:Antigens / Q000378:metabolism*; D005453:Fluorescence; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D008954:Models, Biological; D023041:Xenograft Model Antitumor Assays
chemical_list: D000906:Antibodies; D019138:Antibodies, Blocking; D000941:Antigens
references.citation: Cancer Res. 2008 May 1;68(9):3334-41
references.pmid: 18451160
references.citation: Cancer Immunol Immunother. 2001 Apr;50(2):77-81
references.pmid: 11401028
references.citation: Nature. 2005 Sep 22;437(7058):497-504
references.pmid: 16177780
references.citation: Cancer. 1974 Jan;33(1):103-10
references.pmid: 4810083
references.citation: Cancer Res. 1990 Nov 15;50(22):7382-92
references.pmid: 2224866
references.citation: Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):81-93
references.pmid: 18712381
references.citation: J Nucl Med. 2006 May;47(5):793-6
references.pmid: 16644749
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93
references.pmid: 12359857
references.citation: J Physiol. 2005 Sep 1;567(Pt 2):557-67
references.pmid: 15994186
references.citation: Biochem Pharmacol. 2006 Jun 28;72(1):1-10
references.pmid: 16469301
references.citation: Cancer Res. 2001 Jun 15;61(12):4750-5
references.pmid: 11406547
references.citation: Adv Drug Deliv Rev. 2008 Sep;60(12):1421-34
references.pmid: 18541331
references.citation: Cancer Biother Radiopharm. 2009 Apr;24(2):195-200
references.pmid: 19409041
references.citation: Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8
references.pmid: 17262214
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70
references.pmid: 8962129
references.citation: Cancer Res. 1991 Jun 15;51(12):3102-7
references.pmid: 2039990
references.citation: Scand J Clin Lab Invest. 1974 Oct;34(2):119-22
references.pmid: 4424039
references.citation: Cancer J. 2008 May-Jun;14(3):191-7
references.pmid: 18536559
references.citation: PLoS One. 2009 Nov 30;4(11):e8053
references.pmid: 19956597
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1230-8
references.pmid: 17431103
references.citation: APMIS. 1988 Aug;96(8):701-10
references.pmid: 3415845
references.citation: Biochem J. 1990 Apr 1;267(1):155-62
references.pmid: 1691636
references.citation: J Nucl Med. 2009 Jan;50(1):123-31
references.pmid: 19091906
references.citation: Jpn J Cancer Res. 1998 Mar;89(3):307-14
references.pmid: 9600125
references.citation: Mol Cancer Ther. 2009 Oct;8(10):2861-71
references.pmid: 19825804
references.citation: Nat Biotechnol. 2005 Sep;23(9):1137-46
references.pmid: 16151407
references.citation: J Nucl Med. 2009 Aug;50(8):1340-8
references.pmid: 19617342
references.citation: Microvasc Res. 1989 Jan;37(1):77-104
references.pmid: 2646512
references.citation: Nat Med. 2009 Jan;15(1):104-9
references.pmid: 19029979
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1550-8
references.pmid: 16818514
references.citation: J Nucl Med. 2009 Jul;50(7):1116-23
references.pmid: 19525473
references.citation: J Immunol. 2007 Sep 1;179(5):2815-23
references.pmid: 17709495
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s
references.pmid: 16203810
references.citation: Cancer Biother Radiopharm. 2008 Apr;23(2):158-71
references.pmid: 18454685
references.citation: Nat Biotechnol. 2004 Jun;22(6):701-6
references.pmid: 15133471
references.citation: Trends Pharmacol Sci. 2008 Feb;29(2):57-61
references.pmid: 18179828
references.citation: Cancer Biother Radiopharm. 2008 Oct;23(5):619-31
references.pmid: 18999934
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6154-60
references.pmid: 18829494
references.citation: J Nucl Med. 2009 Feb;50(2):239-49
references.pmid: 19164218
references.citation: Cancer Immunol Immunother. 2008 Jul;57(7):1017-27
references.pmid: 18236042
references.citation: J Nucl Med. 2007 Jun;48(6):995-9
references.pmid: 17504872
references.citation: Mol Pharm. 2009 Mar-Apr;6(2):428-40
references.pmid: 19718796
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17099-104
references.pmid: 17940013